BioNTech Results Presentation Deck

Fix Vac: Leveraging Shared Antigens to Break Immune Tolerance Off-the Shelf Concept: Scalable for multiple indications Vaccine Backbone Optimized, unmodified mRNA ● ● ANTIGEN CASSETTE HI Targeting antigen presenting cells to stimulate antigen-specific T cell responses Strong immunogenicity observed in vivo via TLR-driven adjuvant effect¹ 22 AAAA Poly(A) tail Potent induction of strong ex vivo CD4+ and CD8+ T cell responses ¹ Lipoplex Proprietary RNA-LPX formulation (IV) *****************!!!!!!! T L Th FATPMEAEL (HLA-CW 03:04 /NY-ESO-1) MITT 10 T L Th 10.1% + ששוןווו Antigen-specific CD8+ T cell responses ²: 4 0 10 NY-ESO-1 | Melanoma BNT111, Lipo-MERIT trial 5 10 Shared Antigens Multi-antigen approach per tailored to each indication EVDPIGHLY (HLA-A 01:01 / MAGE-A3) 2.1% 10° Fixed vaccine combination against shared tumor- associated antigens 0 10 MAGE-A3 | Melanoma BNT111, Lipo-MERIT trial RNA-LPX. RNA-Lipoplex; IV, intravenous; TLR7, Toll-like receptor; NY-ESO-1, New York esophageal squamous cell carcinoma-1; MAGE-A3, melanoma-associated antigen 3; HPV-E7, Human papillomavirus (type 16) E7 oncoprotein; HPV, Human papillomavirus; NSCLC, Non small cell lung cancer; HLA, human leukocyte antigen; CD, cluster of differentiation ¹Sahin U, et al. Nature 2020; 585:107-112; 2T cell responses analyzed by ex vivo multimer staining analysis in blood; ³Additional exploratory indication: Ovarian Cancer 10 Fix Vac 6866 10 5.0% HPV16-E7 | Head & Neck Cancer BNT113, HARE-40 trial BIONTECH

View entire presentation